Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD6615 Single Ascending Dose in Healthy Subjects
NCT04055168Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Jul 2019
- Primary completion
- Feb 2020
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of AZD8233 in dyslipidemia (5 cohorts), sponsored by AstraZeneca. Primary endpoint: Number of subjects with adverse events (AEs) and serious adverse events (SAEs). Started Jul 2019; status: terminated.
02
Drugs
AZD8233
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT04055168.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04055168.